VEGFR-1 mAb (Eli Lilly)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVEGFR-1 mAb (Eli Lilly)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonists
TargetsVascular endothelial growth factor receptor 1
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A